Jinyu Baoling Biopharmaceutical Co., Ltd. is affiliated to Inner Mongolia Jinyu Group Co., Ltd. (JINYUGROUP, stock code 600201). It is one of the key enterprises designated by the Ministry of Agriculture for the production of livestock foot-and-mouth disease vaccines. It has become a scientific research, development, production and sales. An integrated high-tech enterprise.

The company is located at No. 58, West Ordos Street, Yuquan District, Hohhot City, the capital of Inner Mongolia Autonomous Region. Its predecessor was Inner Mongolia Biopharmaceutical Factory and was established in 1958. Before 1998, it was affiliated with the Inner Mongolia Animal Husbandry Department and joined Inner Mongolia Jinyu Group Co., Ltd. in 1998. Since then, it has entered the fast lane of enterprise development.

On March 5, 2007, in order to expand and strengthen the biopharmaceutical industry, with the approval of the group company, Jinyu Group invested 50 million yuan on the basis of the Inner Mongolia Biopharmaceutical Factory to integrate internal resources and build a biopharmaceutical industry platform, and established a Jinyu Baoling Biopharmaceutical Co., Ltd.

On February 7, 2007, the entire factory passed the GMP certification of the Ministry of Agriculture. After nearly ten years of continuous innovation and development, the company has the first modern production workshop in the country to pass the GMP certification of the Ministry of Agriculture, two powerful inactivated vaccine workshops and one attenuated freeze-dried live vaccine GMP workshop, and is equipped with a R&D center and a testing center. , three modern facilities that assist in production such as P3 standard animal laboratory, material warehouse, finished cold storage and equipment power. The total construction area is 59,900 square meters, the total purification area is 13,010 square meters, and the total negative pressure area is 4,720 square meters. It successfully passed the workshop's GMP certification three times on December 23, 2002, January 16, 2004, and February 21, 2005, and on February 7, 2007, the entire factory passed the GMP certification of the Ministry of Agriculture. With the approval of experts from the Ministry of Agriculture, our company's current annual production capacity of foot-and-mouth disease vaccine is 2.4 billion milliliters, the largest single variety production capacity in the industry, and has an annual production capacity of 10 billion feathers/head of attenuated freeze-dried live vaccine. More than 60 products in six categories: pigs, cattle, sheep and poultry, forming 7 varieties of foot-and-mouth disease in two categories, 16 varieties of cattle and sheep vaccines, 13 varieties of pig vaccines, and 30 varieties of poultry vaccines in two categories. Product structure. It has established the excellent brand of "Baoling" and provided a large number of high-quality and efficient biological medicines for the prevention and control of livestock and poultry epidemics across the country. Among them, cattle and sheep vaccine production ranks first in the country, especially the double-price inactivated vaccine for cattle and sheep type O-Asia type I foot-and-mouth disease double-price inactivated vaccine has been widely praised by users. The live goat pox vaccine has won the Ministry of Agriculture's Quality Product Award and the Gold Award at the First China Agricultural Expo; Sheep Sanlian Dry Powder The inactivated vaccine won the first China Agricultural Expo high-quality award and the title of famous brand products at the third Agricultural Expo.

The company currently has 478 employees, including 3 researchers, 12 senior veterinarians and other senior technicians, 80 intermediate technicians, and 428 technicians, accounting for 89% of the total number of employees, providing the development of the enterprise. Have strong technical strength.

The company strictly manages production quality in accordance with GMP requirements, adopts advanced antigen purification, concentration technology, emulsification technology, and endotoxin control to improve product quality rapidly, and product quality is deeply trusted by users. In 2004, the company sent the foot-and-mouth disease vaccine produced to the PIRBRIGHT Laboratory, which belongs to the International Organization for Animal Health (OIE) (a authoritative organization specializing in epidemic testing and other work). The test results show that the immune titer is as high as 6.06 PD50. According to the regulations of the International Organization for Animal Health (OIE), foot-and-mouth disease vaccine can be used for immunization as long as it reaches 3.0 PD50 or above, which fully demonstrates that the quality of our company's product has far exceeded the international standard as early as 2004.